Compare Citius Pharmaceuticals Inc (CTXR) vs Vishay Intertechnology Inc. Common Stock (VSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Vishay Intertechnology Inc. Common Stock — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Vishay Intertechnology Inc. Common Stock trades at $34.04 (market cap $5.30B). The key difference: Vishay Intertechnology Inc. Common Stock is far larger — about 389.1× Citius Pharmaceuticals Inc's market cap, and Vishay Intertechnology Inc. Common Stock pays a 1.16% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Vishay Intertechnology Inc. Common Stock for 1 Days on average.
| CTXR | VSH | |
|---|---|---|
Market Cap | $13.62M | $5.30B |
Volume | 132,438 | 3,213,272 |
Sector | Health | Technology |
52-Week High | $1.82 | $64.90 |
52-Week Low | $0.48 | $11.82 |
Typical Hold Time | 17 Days | 1 Days |
Enterprise Value | $3.79M | $5.10B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% in the last session, with a bearish technical signal from moving averages but bullish oscillators. The company reported $7.1M revenue for the first nine months of fiscal 2026 from LYMPHIR sales, yet net losses persist, with a net income margin of -651.27%. Cash flow remains positive due to financing activities, and analyst consensus is strongly bullish with five buy ratings.
The outlook hinges on commercial execution of LYMPHIR, offering growth potential amid high losses. Key risks include sustained negative profitability, cash burn, and competitive pressures. Investors should weigh the speculative growth narrative against fundamental weaknesses.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Vishay Intertechnology Inc. Common Stock
Vishay Intertechnology manufactures discrete semiconductors and passive electronic components. Its products include diodes, MOSFETs, resistors, capacitors, and sensors.
Read more on VSH →
